Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect
| Autor: | Kimihito Kato, Yoshiaki Yamada, Kenji Mitsui, Shigeyuki Aoki, Motoi Tobiume, Remi Katsuda, Masayuki Watanabe, Tomohiro Taki, Takaaki Hasegawa, Yoshiharu Kato, Takahiko Yoshizawa, Nobuaki Honda, Genya Nishikawa, Maki Arakawa, Hiroko Saito, Kogenta Nakamura, Kenji Zennami |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Bladder cancer Oncogene Anthracycline business.industry Pirarubicin Therapeutic effect Urology Cancer Articles General Medicine medicine.disease Immunology and Microbiology (miscellaneous) Internal medicine Toxicity medicine Adverse effect business medicine.drug |
| Zdroj: | Experimental and Therapeutic Medicine. 2:901-905 |
| ISSN: | 1792-1015 1792-0981 |
| Popis: | The aim of this study was to investigate the relationship between tissue concentrations and exposure times or therapeutic effect of an anthracycline anticancer drug, pirarubicin, in bladder cancer tissue after single intravesical administration against superficial bladder cancer. The concentrations of pirarubicin in tumor tissues and serum were measured at designated collection times after a single intravesical administration of pirarubicin (30 mg) in 22 patients with superficial bladder cancer. A wide range of concentrations of pirarubicin in bladder cancer tissue was observed (2.3–125 μg/g of tissue), although serum pirarubicin concentrations were not detected in any of the patients. Recurrence of superficial bladder cancer after transurethral resection of the bladder tumor (TUR-BT) was observed in 2 patients (9%). The concentration of pirarubicin in the tumor tissue tended to be higher as the exposure time increased. There was a weak relationship between the pirarubicin tissue concentration and tumor size. However, no significant relationship between tissue pirarubicin concentrations and the prophylactic effect against intravesical recurrence of bladder cancer after TUR-BT was observed. All patients had no adverse events, such as bladder irritation and local toxicity, caused by the treatment with pirarubicin. These findings suggest that prior to single intravesical administration of pirarubicin to patients with superficial bladder cancer the exposure time and tumor size should be considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|